";s:4:"text";s:5805:" MIRVASO® (brimonidine) topical gel, 0.33%* is the first FDA-approved treatment developed and indicated for persistent facial redness of rosacea Otherwise, click OK to continue. The safety and efficacy of MIRVASO® (brimonidine) topical gel, 0.33%* was evaluated in 2 identical, randomized, vehicle-controlled trials with 553 patients aged 18 years and older. To get your MIRVASO Gel Patient Savings Card, click OK below. �S)�'T��&վu�Ж��O7�5d3W5�r�c\����̺}�� M�@D0e&��W� �+����,VS`�P�?��!ڷ�#%��w��E��g��t�0�۱�+��%#�R�A�M����E�3(��D}V���4�(@̠_�Ely��X�� Put a pea-size amount of medicine on your chin, nose, middle of your forehead, and on each cheek. Cardizem® (diltiazem) Carac® (fluorouracil cream 0.5%) Copaxone® (glatinamir acetate injection) Claritin® (loratadine) Clarinex® (desloratidine) ... Mirvaso® (brimonidine topical gel) Napro® (paclitaxel) Nitro-Dur® (nitroglycerine transdermal patch) Norvasc® (amlodipine) It is an α-2 adrenergic agonist. Risk of symptom exacerbation Skip the missed dose if it is almost time for your next scheduled dose. Start studying Top 200 Drugs of 2019. Visit To get your MIRVASO Gel Patient Savings Card, click OK below. This site is intended for U.S. audiences only. Every gram of Mirvaso contains 3.3mg of brimonidine. ?p���{����qV�4�y��%�y|�&c�����7����D.ا�B-�Ʌ\�m��X�&B/�?���&�_v�o~�p��2����brl�J��y�\��s��b�+?��ׁ ���5O�B�ŷ��2Q��>�����^�m�Lho��"7��v������]¹Y�nH��l��wk� bqxLJ�����'�N�fJei�3� ��
�����;��/f���a�l�U��f7����dzuF���p���$��q�����A*S%�������$�I|�韑����*b,b�E���2? Brimonidine (Mirvaso) is a topical gel indicated for the symptomatic treatment of facial erythema of rosacea in adults. Tell your doctor if you are pregnant or plan to become pregnant during treatment.It is not known whether brimonidine passes into breast milk or if it could harm a nursing baby. The secondary endpoint was 1-grade composite success at 30 minutes on day 1. Mirvaso is contraindicated in children aged less than 2 years because of serious systemic safety risk (see section 4.3). Formulary Exclusions Drug List The primary endpoint for both studies was 2-grade composite success at hours 3, 6, 9, and 12 on day 29. If you are not sure of what to do if you miss a dose, or if you miss more than one dose, contact your healthcare provider.An acute overdose of this medicine is not likely to cause life-threatening symptoms. If you cannot reach your healthcare provider right away, get emergency medical care or call 911 for help): Allergic reaction (hives; itching; rash; trouble breathing; tightness in your chest; swelling of your lips, tongue, and throat).Serious (contact your healthcare provider right away): Extreme skin irritation or redness.Other: Stuffy or runny nose, flushing, temporary burning sensation, blurred vision.When you take this medicine with other medicines, it can change the way this or any of the other medicines work. v�|��L��g�+��&��}�rV�� The Galderma CareConnect Program Patient Savings Card has no cash value and will not be accepted outside of participating pharmacies in the United States. Talk to your doctor about medical concerns. The medicine or ‘active ingredient’ in Mirvaso gel is called brimonidine. Headline Covered and non-covered drugs Drugs not covered — and their covered alternatives for the Value and Value Plus pharmacy plans 2018 Formulary Exclusions Drug List Formulary Exclusions Drug List Study participants were randomized 1:1 to receive either MIRVASO or vehicle gel once daily for 4 weeks. With topicaluse. Patients are required to wear masks and practice physical distancing in our waiting rooms and offices. If you do not wish to leave Mirvaso.com, click CANCEL. Information in this website is not intended as medical advice. Do not breast-feed while taking this medicine without your healthcare provider's approval.Check the label on the medicine for directions about your specific dose. Drugs not covered — and their covered alternatives for the Premier and Premier Plus pharmacy plans. Do not use double doses. Composite success was defined as improvement on both the Clinician Erythema Assessment and Patient Self-Assessment.The long-term safety and efficacy of MIRVASO was studied in a 52-week, multicenter, open-label, non-comparative study with 449 patients with moderate to severe facial erythema of rosacea. Protect it from heat, high humidity, and bright light.____________________________________________________Ask your pharmacist for the best way to dispose of outdated medicine or medicine you have not used. Covered and non-covered drugs . vؼ}s���>�`�����y��������ER:m��|�>���-,o�O.xf��B���
Ni�%^�4S��ViQ���� �'d��D���_���@
�C1��SR����R=��#�0�T�Q��Or6`ˏH�_�?��\%\,Z�H�7WВ&�r�'�I��疸�L80�Г;��?�ܽ�b�8����I�������I$U���{��7��-Qr�������묖 >�fX�����.)ܦ������57����iw��0�'X���d�K�A�*��.
The Galderma® CareConnect Program is brought to you by Galderma Laboratories, L.P.